Literature DB >> 2831307

Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats.

A R Blight1, J A Gruner.   

Abstract

This study examines the effect of the potassium channel blocker 4-aminopyridine (4-AP) on free fall responses (FFR) in the hindlimb muscles of chronically spinal injured cats. The thoracic spinal cord of 7 adult female cats was injured by a standardized contusion method. At 3-7 months post-injury the FFR in 6 hindlimb muscles was recorded electromyographically in each animal, under ketamine sedation. The normal short-latency response to a sudden drop was severely attenuated in all injured animals and practically undetectable in 2 cases. Within 15 min following intravenous administration of 1 mg/kg 4-AP, there was profound augmentation of the amplitude of the FFR and a tendency toward normalization of latency in all animals, though the normal amplitude range was not attained. The same 4-AP dose produced a relatively small increase of FFR amplitude in only 2 of 4 normal, uninjured animals tested. The data are consistent with previous observations that low doses of 4-AP restore conduction in some critically demyelinated axons, and provide support for the hypothesis that conduction block in surviving axons is responsible for a proportion of the dysfunction in chronic spinal injury. Augmentation of FFR in injured animals may also result partly from increased transmitter release in both spinal cord and periphery, due to the presynaptic effects of 4-AP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2831307     DOI: 10.1016/0022-510x(87)90014-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  9 in total

Review 1.  A systematic review of the effects of pharmacological agents on walking function in people with spinal cord injury.

Authors:  Antoinette Domingo; Abdulaziz A Al-Yahya; Yousif Asiri; Janice J Eng; Tania Lam
Journal:  J Neurotrauma       Date:  2012-02-29       Impact factor: 5.269

Review 2.  Molecular mechanisms of acrolein-mediated myelin destruction in CNS trauma and disease.

Authors:  R Shi; J C Page; M Tully
Journal:  Free Radic Res       Date:  2015-04-16

3.  Neurophysiological examination of the corticospinal system and voluntary motor control in motor-incomplete human spinal cord injury.

Authors:  W B McKay; D C Lee; H K Lim; S A Holmes; A M Sherwood
Journal:  Exp Brain Res       Date:  2004-12-23       Impact factor: 1.972

Review 4.  Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons.

Authors:  Riyi Shi; Wenjing Sun
Journal:  Neurosci Bull       Date:  2011-02       Impact factor: 5.203

5.  Parallel Evaluation of Two Potassium Channel Blockers in Restoring Conduction in Mechanical Spinal Cord Injury in Rat.

Authors:  Jessica C Page; Jonghyuck Park; Zhe Chen; Peng Cao; Riyi Shi
Journal:  J Neurotrauma       Date:  2018-03-13       Impact factor: 5.269

Review 6.  4-aminopyridine toxicity: a case report and review of the literature.

Authors:  Andrew M King; Nathan B Menke; Kenneth D Katz; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2012-09

Review 7.  Naturally occurring disk herniation in dogs: an opportunity for pre-clinical spinal cord injury research.

Authors:  Jonathan M Levine; Gwendolyn J Levine; Brian F Porter; Kimberly Topp; Linda J Noble-Haeusslein
Journal:  J Neurotrauma       Date:  2011-03-25       Impact factor: 5.269

8.  Acrolein-mediated conduction loss is partially restored by K⁺ channel blockers.

Authors:  Rui Yan; Jessica C Page; Riyi Shi
Journal:  J Neurophysiol       Date:  2015-11-18       Impact factor: 2.714

9.  Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial.

Authors:  Ji-Hey Lim; Audrey C Muguet-Chanoit; Daniel T Smith; Eric Laber; Natasha J Olby
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.